Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18862964 | 0.86 | NR1H2 (0.40) | NR1H2 | |
| SCHEMBL17542457 | 0.86 | NR1H2 (0.40) | NR1H2 | |
| SCHEMBL17541935 | 0.86 | NR1H2 (0.40) | NR1H2 | |
| SCHEMBL14417561 | 0.81 | KLK7 (0.47) | KLK7NR1H2HCRTR2LMNAKMT2A | |
| SCHEMBL29997387 | 0.81 | KLK7 (0.47) | KLK7NR1H2HCRTR2LMNAKMT2A | |
| SCHEMBL30165876 | 0.80 | NR1H2 (0.44) | NPC1ALOX5APFEN1NR1H2LMNA | |
| SCHEMBL28334115 | 0.78 | NR1H2 (0.44) | NPC1NR1H2ALDH1A1OPRK1 | |
| SCHEMBL28332149 | 0.78 | NR1H2 (0.44) | NPC1NR1H2ALDH1A1OPRK1 | |
| SCHEMBL28332146 | 0.78 | NR1H2 (0.44) | NPC1NR1H2ALDH1A1OPRK1 | |
| SCHEMBL5582903 | 0.77 | BACE1 (0.50) | ALOX5APFEN1NR1H2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2181996-A1 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2010-05-05 | — | — | EP | disclosed |
| US-7498326-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-03-03 | — | — | US | disclosed |
| US-7312212-B2 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2007-12-25 | — | — | US | disclosed |
| US-7109213-B2 | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 2006-09-19 | — | — | US | disclosed |
| US-20060058287-A1 | Gramnegative and Grampositive bacterial infections; substituted Piperidine derivatives specially optionally substituted pyrido [3,2, -b][1,4] thiazin-yl; 6-({(3R,4S)-3-Fluoro-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino }-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one; nontoxic | GLAXO GROUP LIMITED (GB) | 2006-03-16 | — | — | US | disclosed |
| EP-1583537-A3 | PIPERIDINE COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2005-12-14 | — | — | EP | disclosed |
| EP-1583537-A2 | PIPERIDINE COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2005-10-12 | — | — | EP | disclosed |
| US-20050159411-A1 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2005-07-21 | — | — | US | disclosed |
| US-20050085494-A1 | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 2005-04-21 | — | — | US | disclosed |
| EP-1470125-A1 | AMINOPIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-10-27 | — | — | EP | disclosed |
| EP-1470131-A2 | AMINOPIPERIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2004-10-27 | — | — | EP | disclosed |
| WO-2004002490-A2 | PIPERIDINE COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2004-01-08 | — | — | WO | disclosed |
| WO-2003064421-A1 | AMINOPIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003064431-A2 | AMINOPIPERIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085494-A1 | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them | NPEPPS, AASDHPPT, DNPEP | KLK7 3720/4885NPC1 3308/4885ALOX5AP 127/4885 |
| US-20050159411-A1 | Aminopiperidine derivatives | AMPD2, AMPD3, NPEPPS | KLK7 4084/4885NPC1 3780/4885ALOX5AP 395/4885 |
| US-20060058287-A1 | Gramnegative and Grampositive bacterial infections; substituted Piperidine derivatives specially optionally substituted pyrido [3,2, -b][1,4] thiazin-yl; 6-({(3R,4S)-3-Fluoro-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino }-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one; nontoxic | TLR1, TLR2, TLR6 | KLK7 3166/4885NPC1 4227/4885ALOX5AP 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.